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ABSTRACT
Here, we assembled a broad molecular “tool-kit” to interrogate the role of 
metabolic heterogeneity in the propagation of cancer stem-like cells (CSCs). First, we 
subjected MCF7 cells to “metabolic fractionation” by flow cytometry, using fluorescent 
mitochondrial probes to detect PCG1α activity, as well ROS and hydrogen-peroxide 
(H2O2) production; NADH levels were also monitored by auto-fluorescence. Then, the 
various cell populations were functionally assessed for “stem cell activity”, using the 
mammosphere assay (3D-spheroids). Our results indicate that a sub-population of 
MCF7 cells, with increased PGC1α activity, high mitochondrial ROS/H2O2 production 
and high NADH levels, all form mammospheres with a higher efficiency. Thus, it 
appears that mitochondrial oxidative stress and the anti-oxidant response both 
contribute to the promotion of mitochondrial biogenesis and oxidative metabolism in 
CSCs. Further validation was provided by using specific inhibitors to target metabolic 
processes (the NAD+ salvage pathway, glycolysis, mitochondrial protein synthesis 
and OXPHOS), significantly reducing CSC propagation. As a consequence, we have now 
identified a variety of clinically-approved drugs (stiripentol), natural products (caffeic 
acid phenyl ester (CAPE), ascorbic acid, silibinin) and experimental pharmaceuticals 
(actinonin, FK866, 2-DG), that can be used to effectively inhibit CSC activity. We 
discuss the use of CAPE (derived from honey-bee propolis) and Vitamin C, as potential 
natural therapeutic modalities. In this context, Vitamin C was ~10 times more potent 
than 2-DG for the targeting of CSCs. Similarly, stiripentol was between 50 to 100 
times more potent than 2-DG.
INTRODUCTION
Cancer stem-like cells (CSCs) are thought to be 
the root cause of chemotherapy-resistance and radio-
resistance, ultimately leading to treatment failure in 
patients with advanced disease [1-3]. They have been 
directly implicated mechanistically in tumor recurrence 
and metastasis, resulting in poor patient survival [4-6]. 
However, the metabolic basis of the CSC phenotype 
remains largely unexplored. 
Recently, based on unbiased label-free proteomics 
analysis, we proposed that mitochondrial biogenesis may 
be a key driver of the CSC phenotype [7]. A prediction of 
this hypothesis is that high mitochondrial mass would be 
a metabolic biomarker for CSCs. To test this hypothesis 
experimentally, we used a vital dye, called MitoTracker, to 
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stain mitochondria in living cancer cells. This allowed us 
to purify the Mito-high and the Mito-low cell populations 
by flow cytometry. Interestingly, the Mito-high cell 
population showed a clear enrichment of cells with the 
characteristics of CSCs [8-13]. Thus, the use of “metabolic 
fractionation”, using mitochondrial-based probes and 
flow cytometry, is a new successful strategy that also 
provides a functional assay for dissecting how metabolic 
heterogeneity contributes to the CSC phenotype. 
Here, we have expanded this metabolic fractionation 
approach to the use of i) other mitochondrial probes (for 
monitoring mitochondrial biogenesis, ROS production 
and hydrogen peroxide) and ii) NADH auto-fluorescence. 
Our results indicate that increased mitochondrial oxidative 
stress and high NADH levels are both key characteristics 
of the CSC metabolic phenotype. 
This strategic approach also allowed us to identify 
several new weak points, such as NAD+ depletion, for 
metabolically targeting CSCs. 
RESULTS
NAD(P)H auto-fluorescence as a new metabolic 
biomarker for CSCs
Here, we set out to assess the role of cell metabolism 
in generating molecular heterogeneity or diversity in 
cancer cells, with a specific focus on the CSC phenotype. 
To address this issue experimentally, we chose to 
subject the MCF7 cell line to metabolic fractionation via 
flow cytometry (FACS). For this purpose, we employed 
a number of fluorescent probes to specifically monitor 
mitochondrial biogenesis (PGC1α-eGFP), mitochondrial 
ROS production (Dihydro-Rhodamine 123) and 
mitochondrial hydrogen-peroxide levels (H2O2; Mito-
PY1). In addition, the levels of NAD(P)H were monitored 
by auto-fluorescence, at an emission wavelength of 
470-nm. The experimental utility of these probes is 
summarized in Table 1.
In this fractionation scheme, cells containing low- 
or high-levels of a given vital probe were then analyzed 
phenotypically, using the mammosphere assay as a 
measure of “cancer stem cell activity”. A summary of this 
systematic approach is briefly presented schematically in 
Figure 1. 
Interestingly, using this reductionistic experimental 
approach, our results directly show that a particular sub-
population of MCF7 cells, with the highest levels of 
mitochondrial biogenesis, mitochondrial ROS/H2O2, 
and NADH levels, have the highest capacity to efficiently 
generate mammospheres (Figures 2-5). 
As NAD(P)H auto-fluorescence is an intrinsic 
property of cells and does not require the use of any 
exogenous fluorescent probes, we propose that NAD(P)
H auto-fluorescence could be used as a new metabolic 
biomarker for CSC enrichment (Figure 5A). Importantly, 
high levels of NAD(P)H auto-fluorescence are known to 
be a surrogate marker for mitochondrial “power”, high 
OXPHOS capacity and increased ATP production. As 
such, CSCs may be strictly dependent on NAD(P)H to 
maintain their enhanced mitochondrial function. 
As further functional validation, we next examined 
the sensitivity of MCF7 mammosphere formation to 
NAD+ depletion, by employing the well-characterized 
NAMPT inhibitor, namely FK866 [14]. Figure 5B shows 
that mammosphere formation was dramatically inhibited 
by FK866, with an IC-50 of less than 1 nM. Thus, an 
intact NAD+ salvage pathway is strictly required for 
mammosphere formation, supporting our results using 
NAD(P)H auto-fluorescence, which enriched CSC activity 
by more than 5-fold. 
Similarly, as further validation, we also show 
that a known selective inhibitor of mitochondrial 
protein synthesis (the natural antibiotic actinonin; [15]), 
efficiently blocked mammosphere formation, with an IC-
50 between 25 and 50 µM (Figure 6). This is consistent 
with our observations regarding a significant increase in 
mitochondrial biogenesis, as reflected by our studies using 
the PGC1α-eGFP probe. 
Identification of vitamin C as a natural product 
targeting “stemness”
Since the NAMPT inhibitor FK866 suffers 
from a number of serious side effects, including 
Figure 1: Experimental strategy for examining the 
role of metabolic heterogeneity in CSC propagation. 
Our overall strategy for investigating the role of mitochondrial 
metabolism in CSCs, using specific fluorescent probes and 
metabolic fractionation by flow cytometry (FACS) is outlined. 
Specific metabolic inhibitors were also employed to directly 
validate our observations; see Table 1.
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thrombocytopenia, lymphopenia and anemia, as well as 
severe nausea and mild fatigue [16], we sought to identify 
other potentially less toxic metabolic approaches for 
targeting CSCs. 
For this purpose, we examined the activity of a 
number of clinically-approved drugs, natural products, as 
well as experimental pharmaceuticals. Since glycolysis 
is especially critical for maintaining the TCA cycle, 
OXPHOS and overall mitochondrial function, we next 
assessed the effects of known glycolytic inhibitors. 
Interestingly, our results directly show that the 
classical glycolysis inhibitor, namely 2-deoxy-glucose 
(2-DG), inhibits mammosphere formation, with an IC-
50 near 10 mM (Figure 7A). Similarly, we show that 
two other natural products that function as effective 
glycolysis inhibitors, also inhibited mammosphere 
formation. More specifically, vitamin C (ascorbic acid), 
which induces oxidative stress and inhibits the activity of 
GAPDH (a key glycolytic enzyme) [17], also inhibited 
mammosphere formation, with an IC-50 of 1 mM (Figure 
7B). Therefore, vitamin C was ~10 times more potent than 
2-DG at targeting CSC propagation. Interestingly, silibinin 
(the major active constituent of silymarin, an extract of 
milk thistle seeds) [18], which specifically functions as 
an inhibitor of glucose uptake, blocked mammosphere 
formation, with an IC-50 between 200 and 400 µM 
Figure 2: Mitochondrial biogenesis correlates with stemness. PGC-1α is a key regulator of energy metabolism, since it stimulates 
mitochondrial biogenesis. Thus, we generated a stable MCF7 cell line transfected with the promoter of the murine PGC-1α gene linked to 
eGFP, as a surrogate marker of mitochondrial biogenesis. Therefore, using this reporter system, increased GFP fluorescence is a predictor 
of increased PGC-1α levels and/or activity. MCF7-PGC-1α-eGFP cells were first subjected to metabolic fractionation via flow cytometry 
(FACS) to isolate the GFP-high and GFP-low cell populations. These two cell populations were then immediately plated in low-attachment 
cell culture plates, to assess their capacity for mammosphere formation. Importantly, GFP-high cells showed an ~1.5-fold increase in their 
capacity for mammosphere formation, relative to GFP-low cells. These results suggest that there is a clear correlation between increased 
PGC-1α activity and stemness in cancer cells. GFP-high = highest or top 10% GFP intensity; GFP-low = lowest or bottom 10% GFP 
intensity. Bar graphs show the mean ± SEM, t-test, two-tailed test. *p < 0.05. N = 3 independent experiments. A representative FACS tracing 
is presented in panel A. and quantitation of mammosphere formation is shown in panel B.
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Figure 4: Increased mitochondrial hydrogen peroxide (H2O2) production contributes to stemness. MCF7 cells were first 
live-stained with a fluorescent probe [Mitochondria peroxy yellow 1 (MPY1)] to monitor mitochondrial H2O2 production. Then, MPY1-
stained MCF7 cells were subjected to metabolic fractionation by flow cytometry (FACS), to isolate the MPY1-high, -low and -negative 
cell populations. Each cell population was then plated in low-attachment cell culture plates, to assess their capacity for mammosphere 
formation. Note that the MPY1-high cell population showed a 2.1-fold increase in mammosphere formation, relative to MPY1-negative 
cells. Therefore, high mitochondrial H2O2 production directly correlates with CSC activity. MPY1-high = highest or top 5% intensity; 
MPY1-low = lowest or bottom 5% intensity; MPY1-negative = lowest possible intensity (0 to 2%). Bar graph shows the mean ± SEM, t-test, 
two-tailed test. ***p < 0.0001. N = 3 independent experiments. A representative FACS tracing is presented in panel A. and quantitation of 
mammosphere formation is shown in panel B. 
Figure 3: Increased mitochondrial ROS production contributes to stemness. MCF7 cells were first live-stained with a 
fluorescent probe [dihydro-rhodamine 123 (DHR)] to monitor mitochondrial ROS production. Then, DHR-stained MCF7 cells were 
subjected to metabolic fractionation by flow cytometry (FACS), to isolate the DHR-high, -low and -negative cell populations. Each cell 
population was then plated in low-attachment cell culture plates, to assess their capacity for mammosphere formation. Note that the DHR-
high cell population showed a 2.3-fold increase in mammosphere formation, relative to DHR-negative cells. Therefore, high mitochondrial 
ROS production directly correlates with CSC activity. DHR-high = highest or top 10% intensity; DHR-low = lowest or bottom 10% 
intensity; DHR-negative = lowest possible intensity (0 to 4%). Bar graphs show the mean ± SEM, t-test, two-tailed test. *p < 0.05, ***p 
< 0.0001. N = 3 independent experiments. A representative FACS tracing is presented in panel A. and quantitation of mammosphere 
formation is shown in panel B. 
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(Figure 7C). Finally, the FDA-approved drug stiripentol, 
which behaves as an LDHA inhibitor [19], blocked 
mammosphere formation with an IC-50 between 100 and 
200 µM (Figure 7D). Thus, stiripentol was the most potent 
glycolysis inhibitor that we identified for targeting CSCs 
and it was 50 to 100 times more potent than 2-DG. 
Identification of CAPE as a natural product that 
metabolically targets mitochondria and CSC 
activity
Honey-bee propolis (a.k.a., “bee glue”) is a 
resinous-like substance that bees manufacture as a sealant 
for filling unwanted crevices in their hive [20]. Propolis 
has a strong history of medicinal use, dating back more 
than 2,000 years [20-22]. In fact, caffeic acid phenyl ester 
(CAPE), a key component of honey-bee propolis, has 
potent anti-cancer properties [22]. However, CAPE’s exact 
mechanism of action remains largely unknown. 
Because of it aromatic ring structure (Figure 8), we 
speculated that CAPE might function as a potent inhibitor 
of oxidative mitochondrial metabolism. To test this 
hypothesis, we examined its metabolic effects on MCF7 
cell in culture, using the Seahorse XFe96 Metabolic Flux 
Analyzer. Indeed, Figures 9 and 10 directly show that 
CAPE quantitatively inhibits the mitochondrial oxygen 
consumption rate (OCR) and, in turn, induces the onset of 
aerobic glycolysis (ECAR). 
Next, we tested the effects of CAPE on the ability 
of MCF7 cells to form 3D mammospheres, under 
anchorage independent growth conditions. Interestingly, 
Figure 11A illustrates that CAPE significantly reduces 
mammosphere formation, with an IC-50 of approximately 
2.5 µM. However, it was less effective on adherent “bulk” 
cancer cells, with an IC-50 of 10 µM (Figure 11B). As 
such, CAPE showed a 4-fold selectivity for targeting CSC 
propagation, as compared with adherent MCF7 monolayer 
cells. In addition, at a concentration of 25 µM, CAPE 
was twice as toxic for MCF7 cancer cells, as compared 
with normal fibroblasts. At this concentration, ~60% of 
normal fibroblasts survived, while >70% of cancer cells 
were eliminated. Thus, CAPE shows a clear selectivity 
for targeting CSCs and adherent cancer cells, relative to 
normal fibroblasts. 
Often CSCs are associated with an epithelial 
mesenchymal transition (EMT) phenotype, resulting 
in an increased capacity for cell migration [23]. As a 
consequence, we also tested the effects of CAPE on MCF7 
cell migration, using a standard “scratch assay”. In this 
assay system, cell migration is monitored via “wound 
Figure 5: Increased NAD(P)H levels directly correlate with stemness. A. NAD(P)H auto-fluorescence. NAD(P)H levels are 
known to directly correlate with mitochondrial oxidative capacity (OXPHOS), as well as anti-oxidant capacity. NAD(P)H generates a 
significant amount of cellular auto-fluorescence and is detectable by its emission peak at 470-nm. To examine the possible contribution of 
NAD(P)H to stemness, MCF7 cells were subjected to metabolic fractionation by flow cytometry (FACS), to isolate the NAD(P)H-high, 
-low and -negative cell populations. Each cell population was then plated in low-attachment cell culture plates, to assess their capacity for 
mammosphere formation. Note that the NAD(P)H-high cell population showed a 5.4-fold increase in mammosphere formation, relative to 
the NAD(P)H-negative cells. Therefore, high cellular NAD(P)H levels directly correlate with CSC activity. NAD(P)H-high = highest top 
10% intensity; NAD(P)H-low = lowest bottom 10% intensity; NAD(P)H-negative = lowest possible intensity (no auto-fluorescence). B. 
Effects of the inhibitor FK866. To induce cellular depletion of NAD(P)H, we used a known inhibitor of the NAD+ salvage pathway. Note 
that treatment with FK866 dose-dependently inhibited mammosphere formation, with an IC-50 of less than 1 nM. Bar graphs are shown as 
the mean ± SEM, t-test, two-tailed test. ***p < 0.0001. N = 3 independent experiments.
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closure”. Interestingly, Figure 12 shows that treatment 
with CAPE (25 µM for 24 hours) significantly reduced 
“wound closure” by ~70%. 
Thus, we conclude that CAPE functions as 
a “natural” mitochondrial OXPHOS inhibitor, that 
preferentially targets the CSC sub-population. This could 
explain CAPE’s known anti-cancer properties. 
DISCUSSION
Here, we interrogated how metabolic heterogeneity 
plays a key role in the generation of CSCs. More 
specifically, we employed metabolic fractionation 
by flow cytometry, to assess the potential role of i) 
mitochondrial biogenesis, ii) oxidative stress (ROS and 
H2O2 production) and iii) anti-oxidants, such as NAD(P)
H, in CSC propagation (Figure 13). Our data directly 
shows that a small fraction of the total cell population, 
characterized by increased PGC1α activity, high 
mitochondrial ROS/H2O2 and high NADH levels, has the 
ability to survive and grow under anchorage-independent 
conditions, driving mammosphere formation. In order to 
carefully validate our observation, we used a battery of 
selective metabolic inhibitors to target specific energetic 
pathways, significantly reducing and/or eliminating CSC 
propagation. Thus, we have now identified a number 
Figure 6: Actinonin, a naturally-occurring 
inhibitor of mitochondrial protein synthesis, blocks 
mammosphere formation. Actinonin is a naturally-
occurring antibiotic. However, actinonin also functions as an 
inhibitor of mitochondrial protein translation, by targeting a 
human mitochondrial protein, known as peptide deformylase 
(abbreviated as PDF). PDF is required to remove the formyl-
group from the initiator methionine of mitochondrial proteins 
synthesized on mitochondrial ribosomes. Note that actinonin 
inhibited mammosphere formation, with an IC-50 between 25 
and 50 µM. The bar graph shows the mean ± SEM, t-test, two-
tailed test. ***p < 0.0001. N = 3 independent experiments.
Figure 7: Glycolysis inhibitors also block mammosphere formation. Here, we examined if 4 distinct glycolysis inhibitors have 
the capacity to block mammosphere formation: A. 2-deoxy-glucose (2-DG); B. vitamin C (ascorbic acid); C. silibinin; and D. stiripentol. 
Note that the two most potent glycolysis inhibitors that we identified were silibinin and stiripentol. Silibinin, which functionally blocks 
glucose uptake, inhibited mammosphere formation, with an IC-50 between 200 and 400 µM. Similarly, the FDA-approved drug stiripentol, 
which behaves as an LDHA inhibitor, blocked mammosphere formation with an IC-50 between 100 and 200 µM. Bar graphs are shown as 
the mean ± SEM, t-test, two-tailed test. **p < 0.005, ***p < 0.0001. N = 3 independent experiments. 
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of clinically-approved drugs, natural substances and 
experimental drugs that can be used to effectively inhibit 
CSC activity. We highlight the utility of certain natural 
products, such as Silibinin, Vitamin C and CAPE, that 
could be used to therapeutically target CSCs. Silibinin 
is the major active component of silymarin, which is an 
extract prepared from milk thistle seeds.
NADH auto-fluorescence: A new biomarker for 
CSCs
NADH fluorescence is the dominant form of auto-
fluorescence observed in living cells [24,25]. Interestingly, 
previous studies have shown that normal intestinal 
crypt stem cells have the highest levels NADH auto-
fluorescence [26], relative to other intestinal cell types. 
Figure 8: Chemical structure of caffeic acid phenyl 
ester (CAPE), a key component of honey-bee propolis. 
The presence of two aromatic rings in CAPE conveys significant 
hydrophobicity upon the molecule, which could increase 
its affinity for cellular membranes, such the mitochondrial 
membrane. 
Figure 9: Treatment with CAPE lowers mitochondrial 
respiration. The metabolic OCR profile of MCF7 cells 
grown in monolayers, after 72 hours of treatment with CAPE, 
was examined using the Seahorse XFe96 analyser (Top panel, 
representative experiment). The bar graph, in the Lower 
panel, shows that the all the parameters relative to the oxygen 
consumption (OCR), are significantly decreased by both 
concentration of CAPE, 10 µM and 25 µM, as compared to the 
vehicle-treated control cells (DMSO). The bar graph shows the 
mean ± SEM, t-test, two-tailed test. **p < 0.005, ***p < 0.0001. 
N = 3 independent experiments. 
Figure 10: Treatment with CAPE increases glycolysis. 
The metabolic ECAR profile of MCF7 cells grown in monolayers, 
after 72 hours of treatment with CAPE, was examined using 
the Seahorse XFe96 analyser (Top panel, combination of three 
experiments). The bar graph, in the Lower panel, shows that 
glycolysis (measured after addition of D-glucose) is increased 
after treatment with CAPE at the concentrations of 10 µM 
and 25 µM, as compared to the vehicle-treated control cells 
(DMSO). Data are presented in the graph as combination of N = 
3 independent experiments. Bar graphs are shown as the mean 
± SEM, t-test, two-tailed test. ***p < 0.0001. N = 3 independent 
experiments. 
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So, high NADH is a property that is conserved between 
normal and cancerous stem cells. Previous studies have 
also shown that when non-CSCs and CSCs are both fed 
mitochondrial fuels (such as L-lactate or ketone bodies), 
that CSCs quantitatively produce more NADH in response 
to this stimulus [27]. Similarly, Heeschen and colleagues 
have previously shown that FAD auto-fluorescence is 
also an excellent biomarker for CSCs [28]; however, they 
did not examine the utility of NADH as a biomarker for 
CSCs in their studies [29]. Interestingly, high levels of 
NADH auto-fluorescence are a known to be a surrogate 
marker for mitochondrial “power”, high OXPHOS 
capacity and increased ATP production. Thus, CSCs 
may be strictly dependent on NADH to maintain their 
enhanced mitochondrial function. In accordance with this 
hypothesis, NAD+ depletion, using the NAMPT inhibitor 
FK866, potently blocked mammosphere formation, with 
an IC-50 of less than 1 nM. 
Vitamin C: Targeting metabolism and glycolysis 
in CSCs
The Noble Prize winner, Linus Pauling, was among 
the first to describe and clinically test the efficacy of 
Vitamin C, as a relatively non-toxic anti-cancer agent 
[30]. More recently, Lew Cantley’s group has revisited 
the mechanism(s) by which Vitamin C targets cancer cells 
[17]. Interestingly, they showed that Vitamin C has two 
mechanisms of action. First, it is a potent pro-oxidant, that 
actively depletes the reduced glutathione pool, leading 
to cellular oxidative stress and apoptosis in cancer cells. 
Moreover, it also behaves as an inhibitor of glycolysis, by 
targeting the activity of GAPDH, a key glycolytic enzyme. 
However, its effects on CSC activity was not previously 
evaluated. Here, we show that Vitamin C can also be used 
to target the CSC population, as it is an inhibitor of energy 
metabolism that feeds into the mitochondrial TCA cycle 
and OXPHOS. Similar results were also obtained with 3 
other glycolysis inhibitors, namely 2-DG, silibinin and 
stiripentol. Importantly, stiripentol is a clinically-approved 
drug, but its use is mainly restricted to the treatment of 
epileptic seizures in children, and not for cancer therapy 
[19]. Thus, Vitamin C may prove to be promising agent 
for new clinical trials, aimed at testing its ability to 
reduce CSC activity in cancer patients, as an add-on to 
more conventional therapies, to prevent tumor recurrence, 
further disease progression and metastasis. Interestingly, 
a breast cancer based clinical study has already shown 
that the use of Vitamin C, concurrent with or within 
6 months of chemotherapy, significantly reduces both 
tumor recurrence and patient mortality [31,32]. However, 
the mechanism underlying its potential clinical benefit 
remained obscure. Similarly, Vitamin C treatment inhibits 
tumor growth in murine animal models in vivo [33].
CAPE: Targeting mitochondrial OXPHOS in 
CSCs
CAPE is another natural product that we identified 
which mechanistically targets oxidative mitochondrial 
metabolism and, as a consequence, CSC activity. We 
directly show, using the Seahorse metabolic flux analyzer, 
Figure 11: CAPE potently blocks mammosphere formation. A. 3D-sphere formation. MCF7 cells were plated in low-attachment 
cell culture plates (6-well format), to assess the ability of CAPE to inhibit mammosphere formation. Note that CAPE treatment was 
sufficient to significantly reduce mammosphere formation, with an IC-50 of approximately 2.5 µM. B. Cell viability. The effects of CAPE 
on the viability of adherent cells (MCF7 cells and hTERT-BJ1 fibroblasts) was assessed in parallel, using the SRB assay, in a 96-well 
format. Note that CAPE significantly reduces the viability of MCF7 cells, with an IC-50 of 10 µM. Similar results were obtained with 
hTERT-BJ1 cells. Cell viability was assessed after 72 hours of treatment. Bar graphs are shown as the mean ± SEM, t-test, two-tailed test. 
*p < 0.05, ***p < 0.0001. N = 3 independent experiments.
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that CAPE quantitatively reduces mitochondrial oxygen 
consumption (OCR), while inducing a reactive increase 
in glycolysis (ECAR). As such, it potently inhibits 
mammosphere formation with an IC-50 of ~2.5 µM. 
Similarly, it also significantly inhibits cell migration. 
Therefore, further metabolic studies using CAPE and 
other natural components of honey-bee propolis may be 
warranted. 
CONCLUSIONS
In summary, we have discovered that NAD(P)
H auto-fluorescence and several mitochondrial-based 
fluorescent probes can all be employed to enrich for a 
population of cells with the characteristics of CSCs. In 
accordance with these observations, we also demonstrate 
that 7 different inhibitors of key energetic pathways can 
be used to effectively block CSC propagation, including 
three natural products (silibinin, ascorbic acid and CAPE). 
Future studies will be necessary to test their potential for 
clinical benefit in cancer patients. 
MATERIALS AND METHODS
Materials
MCF7 cells were originally purchased from the 
ATCC. The lentiviral vector encoding the promoter of 
the murine PGC1α gene, linked to the eGFP reporter, 
and containing a puromycin-resistance cassette, was 
custom synthesized by GenecopoeiaTM (Maryland, 
USA; mPGC1α-eGFP-Puro-R). This construct was 
then used to stably transduce MCF7 cells. Media for 
cell culture was DMEM (D6546, Sigma-Aldrich). Cell 
culture media (DMEM/F12) for spheroid culture was 
purchased from Life Technologies. Caffeic acid phenetyl 
ester (CAPE), sulforhodamine B (SRB), the glycolytic 
inhibitor 2-Deoxy-D-Glucose (2-DG), L-ascorbic acid, 
mitochondria peroxy yellow 1 (Mito-PY1), dihydro-
rhodamine 123, and FK866 hydrochloride hydrate, were 
all purchased from Sigma-Aldrich. 
Generation of stably-transduced MCF7 cells
MCF7 cells were transduced with a lentiviral vector 
encoding the following reporter plasmid: mPGC1α-eGFP-
Figure 12: CAPE decreases the migratory capacity of 
MCF7 cells. MCF7 cell migration was monitored using an 
in vitro scratch assay. Images were acquired with the IncuCyte 
Zoom instrument at 0 and 24 hours. The Upper panel of the 
figure shows representative images. MCF7 were treated with or 
without CAPE, at a concentration of 25 uM. Note that CAPE-
treated MCF7 cells migrated slower, as compared to vehicle-
treated MCF7 cells. In the Lower panel, quantification of cell 
migration is presented as % wound-closure. Bar graphs are 
shown as the mean ± SEM, t-test, two-tailed test. ***p < 0.0001. 
Scale bar = 250 µm. N = 3 independent experiments.
Figure 13: Mitochondrial oxidative stress drives 
mitochondrial biogenesis and the anti-oxidant 
response, leading to increased mitochondrial 
metabolism and stemness. We summarize here our overall 
findings schematically, with a focus on how mitochondrial 
ROS and H2O2 production may be a trigger, for driving 
mitochondrial oxidative stress, ultimately leading to increased 
mitochondrial oxidative metabolism in CSCs. Pharmaceuticals, 
chemical inhibitors, or natural products that we have identified 
to target CSCs, which interfere with a specific metabolic process 
or function, are shown in BLUE. 
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Puro-R. Briefly, the lentiviral vector was transfected into 
the 293Ta packaging cells, following the manufacturer’s 
instructions. Two days post-transfection, the cell culture 
supernatant was collected and centrifuged and used to 
infect MCF7 cells. After lentiviral transduction, MCF7 
cells were selected for 12 days in puromycin (2 µg/ml).
FACScan analysis and sorting
MCF7 cells were subjected to metabolic 
fractionation using either the BD FACSAriaTM III and 
BD InfluxTM cells sorters. Data were analyzed using 
FlowJo software (Tree Star, Ashland, OR). Different cell 
populations were isolated and subjected to mammosphere 
analysis. 
Mammosphere formation (3D-Spheroid culture)
A single cell suspension was prepared using 
enzymatic (1x Trypsin-EDTA, Sigma Aldrich, #T3924), 
and manual disaggregation (25 gauge needle) was 
used to create a single cell suspension. Five thousand 
cells were plated with in mammosphere medium 
(DMEM-F12/B27/20ng/ml EGF/PenStrep), under non-
adherent conditions, in six wells plates coated with 
2-hydroxyethylmethacrylate (poly-HEMA, Sigma, 
#P3932) [34]. Cells were grown for 5 days and maintained 
in a humidified incubator at 37°C at an atmospheric 
pressure in 5% (v/v) carbon dioxide/air. After five days 
of culture, the number of spheres with diameter >50 µm 
were counted.
Mitochondrial ROS production
To measure mitochondrial ROS production, we used 
a well-known fluorogenic vital probe, namely dihydro-
rhodamine 123 (Cat. No. D1054). For this purpose, 
samples containing 5 x 106 MCF7 cells (volume 500 µl) 
were incubated for 10 min at 37oC, together with dihydro-
rhodamine 123 at 10 µM. Then, cold PBS was added and 
the samples were FACS sorted based on the intensity of 
the fluorochrome. The three cell populations obtained by 
sorting were seeded under non-adherent conditions and 
tested for their mammosphere- forming ability. 
Mitochondrial hydrogen peroxide production
For the detection of mitochondrial hydrogen 
peroxide production, we used Mito-PY1 as a vital 
fluorescent dye (Cat. No. SML0734). Live cells under 
adherent conditions were labelled with Mito-PY1 
(10 µM) in a PBS solution. After 45 min, Mito-PY1 
was removed and replaced with fresh warm PBS. The 
washes were repeated one more time and the cells were 
trypsinized, resuspended in PBS and were separated by 
flow cytometry. Based on their fluorescence intensity, the 
MCF7 were fractionated and sorted into three distinct cell 
populations: very low fluorescent cells, low 5% and top 
5% GFP cells. The cells were immediately plated under 
non-adherent conditions at the density of five thousands 
cells in each well of a six wells-plate to evaluate their 
mammosphere-forming ability. 
NAD(P)H measurements and treatment with 
FK866 
To optically monitor the levels of mitochondrial 
OXPHOS in MCF7 cells, it is possible to measure NADH 
auto-fluorescence by FACS analysis [24,25]. After UV 
excitation, NADH emits auto-fluorescence at 470-nm. 
So, we used the fluorescence properties of NADH to sort 
MCF7 cells into three distinct populations, based on their 
cellular auto-fluorescence. 
Afterwards, we tested their mammosphere-forming 
ability. Furthermore, we investigated the effect of 
FK866, a potent inhibitor of the NAD+ salvage pathway 
biosynthesis, on the mammosphere-forming ability of 
the sorted cell populations. As it is difficult to distinguish 
between NADH and NADPH auto-fluorescence (both emit 
at 470-nm), the values observed represent the sum of these 
two molecules: NAD(P)H auto-fluorescence. In contrast, 
FAD emits auto-fluorescence at 525-nm. Thus, NAD(P)H 
and FAD auto-fluorescence are distinct. 
Metabolic flux analysis
Extracellular acidification rates (ECAR) and 
oxygen consumption rates (OCR) were analysed using 
the Seahorse XFe96 bioenergetic analyzer (Seahorse 
Bioscience, MA, USA). MCF7 cells were maintained 
in DMEM supplemented with 10% FBS (fetal bovine 
serum), 2 mM GlutaMAX, and 1% Pen- Strep. Fifteen 
thousand MCF7 cells were seeded per well, into XFe96-
well cell culture plates, and incubated at 37°C in a 5% 
CO2 humidified atmosphere. After 72 hours, MCF7 
cells were washed in pre-warmed XF assay media, as 
previously described. ECAR and OCR measurements 
were normalized for cell protein content, by the SRB 
colorimetric assay. Data sets were analyzed using XFe-96 
software and Excel software. 
Cell migration: in vitro scratch assay
MCF7 cells were seeded in 12 wells-plates to create 
a confluent monolayer. Cell monolayers were then scraped 
to create a scratch with a p-200 pipet tip. Plates were 
incubated in the IncuCyteTM Zoom (Essen Bioscience) in 
5% CO2 at 370C for 24 hours. Complete culture medium 
Oncotarget11www.impactjournals.com/oncotarget
containing 10% FBS, -/+ CAPE 25 µM was used. The 
images were acquired and scanned over a period of 24 
hours. Values for migration were obtained after scanning 
the whole wells (with a 4X objective) and represent the 
average of three independent experiments. The rate of 
the migration was evaluated using Image-J software, to 
measure “wound closure”.
Statistics
All data are presented as the mean ± SEM. The 
Student’s t-test was used. P < 0.05 was considered 
statistically significant.
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